Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.30 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
| ▸ | ITGAV | P06756 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.30 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.30 |
| ▸ | ITGAL | P20701 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3569222 | 0.78 | — | — | |
| Water SCHEMBL10621554 | 0.77 | GAA (0.31) | — | |
| Hydrochloric Acid SCHEMBL10660266 | 0.75 | GAA (0.30) | — | |
| SCHEMBL10555075 | 0.74 | — | — | |
| SCHEMBL18457871 | 0.71 | BRD4 (0.30) | — | |
| SCHEMBL12496506 | 0.70 | TNKS2 (0.38) | — | |
| SCHEMBL11983596 | 0.70 | — | — | |
| SCHEMBL12844975 | 0.70 | — | — | |
| SCHEMBL12845184 | 0.70 | — | — | |
| SCHEMBL1032285 | 0.70 | TDO2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3402797-B1 | HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2020-02-19 | — | — | EP | disclosed |
| US-9782387-B2 | Compositions and methods for treating hematological malignancies | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2017-10-10 | — | — | US | disclosed |
| EP-3087068-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | Tel HaShomer Medical Research Infrastructure and Services Ltd. (IL) | 2016-11-02 | — | — | EP | disclosed |
| US-20160303080-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2016-10-20 | — | — | US | disclosed |
| US-9303027-B2 | Kappa opioid receptor agonists | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-04-05 | — | — | US | disclosed |
| US-9303027-B2 | Kappa opioid receptor agonists | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-04-05 | — | — | US | disclosed |
| WO-2015097691-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. (IL) | 2015-07-02 | — | — | WO | disclosed |
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2012012410-A2 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
| EP-1536783-B1 | SOLID FORMULATIONS COMPRISING AN INDOLINONE COMPOUND | PFIZER ITALIA SRL (IT) | 2008-08-06 | — | — | EP | disclosed |
| EP-0023592-B1 | PROCESS FOR PREPARING 4-HYDROXYCARBAZOLE | Roche Diagnostics GmbH (DE) | 1983-03-30 | — | — | EP | disclosed |
| US-4273711-A | Process for the preparation of 4-hydroxycarbazole | BOEHRINGER MANNHEIM GMBH (DE) | 1981-06-16 | — | — | US | disclosed |
| EP-0023592-A1 | Process for preparing 4-hydroxycarbazole | Roche Diagnostics GmbH (DE) | 1981-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OPRD1 | ITGB3 2195/4885ITGB2 3558/4885ITGB1 2739/4885 |
| US-20160303080-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | MCL1, BCL9, THPO | ITGB3 2201/4885ITGB2 1512/4885ITGB1 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.